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Available online 9 September 2016This study investigates effects of dipeptide balenine, as a major component of whale meat extract (hereafter,
WME), supplementation on senescence-accelerated mouse prone 8 (SAMP8), an Alzheimer's disease (AD)
model at level of learning and memory formation and brain expression proﬁles genome-wide in brain. Mice
fed experimental balenine (+WME) supplemented diet for 26 weeks were subjected to four behavioral tests –
open ﬁeld, Y-maze, novel object recognition, and water-ﬁlled multiple T-maze – to examine effects on learning
and memory. Brain transcriptome of SAMP8 mice-fed the WME diet over control low-safﬂower oil (LSO) diet-
fed mice was delineated on a 4 × 44 K mouse whole genome DNA microarray chip. Results revealed the WME
diet not only induced improvements in the learning andmemory formation but also positivelymodulated chang-
es in the brain of the SAMP8 mouse; the gene inventories are publically available for analysis by the scientiﬁc
community. Interestingly, the SAMP8mousemodel presentedmany genetic characteristics of AD, and numerous
novel molecules (Slc2a5, Treh, Fbp1, Aldob, Ppp1r1a, DNase1, Agxt2l1, Cyp2e1, Acsm1, Acsm2, and Pah) were re-
vealed over the SAMR1 (senescence-acceleratedmouse resistant 1)mouse, to be oppositely regulated/recovered
under the balenine (+WME) supplemented diet regime by DNA microarray and bioinformatics analyses. Our
present study demonstrates an experimental strategy to understand the effects of dipeptide balenine, prominetly
contained inmeat diet, on SAMP8, providing new insight into whole brain transcriptome changes genome-wide.
The gene expression data has been deposited into the Gene Expression Omnibus (GEO): GSE76459. The data will
be a valuable resource in examining the effects of natural products, andwhich could also serve as a humanmodel
for further functional analysis and investigation.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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The dipeptide, balenine (beta-alanyl-N tau-methyl histidine), has
been identiﬁed long back in the extracts of muscles from 9 species of
mammal, including man and chicken by comparative chromatographySciences, Tsukuba International
-1-1 Tennodai, Tsukuba, Ibaraki
al).
ly to this work.
. This is an open access article underin combination with amino acid sequencing techniques [1]. As men-
tioned by Harris and Milne, 1987, “the dipeptide contained equimolar
amounts of beta-alanine and N tau-methyl histidine with beta-alanine
as the N-terminus [1]. Further, it was proposed that balenine, like
carnosine and anserine is to be regarded as a normal constituent of
muscle” [1].
To brieﬂy give a background to the current study, our interest in
looking at novel molecules for their potential beneﬁcial effects on the
human body was developed while investigating the nucleoprotein
(NP) from salmon soft roe [2], especially how NP diet affects the brain
and neurodegenerative disorders/diseases therein [3]. Among thethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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disorders, such as Parkinson's disease andAlzheimer's disease (AD), and
which seriously limit the health and well-being of the world's aging
population. Thus, the brain (and especially neurodegenerative disor-
ders/diseases) becomes a hot topic for current researchers in this ﬁeld,
including our own group. With this backdrop, our present research ex-
amines the imidazole dipeptide, balenine – a major component of the
meat, especially whale meat that is known to contain balenine in high
concentration [4–6], in context of it being an important anti-fatigue
food. This assumption is based on previous research, which shows the
anti-fatigue effects with a ddY [7] swimming mouse model [8], and in
humans under physical load and by daily activities [9]. These two stud-
ies [8,9] suggested that whale meat through diet, in mice and as a sup-
plement for human subjects, was most probably involved in “high
efﬁciency for muscle endurance in mice” [8] and “attenuating high
workload induced fatigue in humans” [9], indicating possible utilization
of the whale meat as an anti-fatigue food, andmaybemore. As balenine
is the major constituent, and the objective of our research, we used the
whale meat extract (WME) as a test sample to conduct the present re-
search. The availability of the whale meat at Kyodo Senpaku Co. Ltd.
(Tokyo, Japan) also helped to utilize it for our research as a candidate
meat sample. It should be re-emphasized that we were primarily
interested in the imidazole dipeptide, balenine, contained in the meat
as an essential molecule/compound [4–6] behind these observed
beneﬁts for human health [8,9], and not about whaling per se. To note,
research into human wellness includes studies into the major life-
style diseases and the beneﬁts of not only searching for a suitable and
healthy lifestyle but also and more importantly utilizing the potential
of naturally occurring and protective compounds in our environment
(plant or animal).
In the present study, we report the results of our investigation into
the effects of balenine through WME-supplemented diet in a mouse
model of AD, the senescence-accelerated mouse prone 8 (SAMP8),
using behavior and molecular genetic approaches to better understand
the central nervous system dysfunction [10]. The reason for using
SAMP8 is that it is a widely used model for AD and numerous studies
have been conducted in relation to cognitive impairment (learning
and memory deﬁcits) and pathology, including oxidative stress and
gene and protein expression analyses (for review see [11,12]). Our pres-
ent study builds up on two sets of experiments investigating the exper-
imental balenine (+WME)-supplemented diet over the low-safﬂower
oil (hereafter, LSO) diet as a control diet, on SAMP8 and SAMR1 (senes-
cence-acceleratedmouse resistant 1) learning andmemory deﬁcits (ex-
periment 1) andwhole genomeDNAmicroarray-based transcriptomics
proﬁling in conjunction with Ingenuity Pathway Analysis (IPA; experi-
ment 2). Results revealed that balenine (+WME) supplementation in
the diet of SAMP8 mouse resulted in an increase in the level of learning
andmemory formation and positive changes in the transcriptomeof the
brain in regards to cellular energy metabolism, suggested through the
observation of recovery of gene expressions in the SAMP8 model over
the not supplemented (control diet) mouse, and the potential involve-
ment of the dipeptide balenine, as a major source of the beta-amino
acid, beta-alanine, and other peptides to the cells.
2. Results
2.1. The experimental design and strategy for investigating effects of
balenine (+WME)-supplemented diet on SAMP8 mice
With an aim to investigate the potential beneﬁcial effects of balenine
(+WME) we have here utilized a mouse model of SAMP8, and which
also serves as an AD model. In this study, we linked behavioral analysis
with omics approach via whole genome DNA microarray chip experi-
ment and IPA analysis to reveal changes in the SAMP8 mice brain with
or without WME supplemented diet and over the SAMR1 mice brain.
As schematically presented in Fig. 1, the SAMP8 and SAMR1 micewere fed WME or control LSO diets for 26 weeks, followed by tests to
determine improvements in learning and memory and thereafter
extraction of total RNA for unraveling the brain transcriptome to ﬁrst
identify changes genome-wide and then attempt to delineate potential
molecular factors behind the suggested improvements in learning and
memory. Previous studies have also reported the WME-induced
anti-fatigue effect in mouse and human [8,9], and that was one
reason for carrying out the present research. The other reason for
why the meat component was used on the SAMP8 mice model, we
provide a preliminary data on the radical (superoxide anion, O2−)
scavenging activity between different edible parts of the whale oil
and meat (see Online Resource 1 [13]). These data revealed that
meat strongly removed O2– compared to other groups in vitro, sug-
gesting its potential as an anti-oxidant or containing anti-oxidative
properties, which was useful in context of the SAMP8 mice model.
Next, we present below the results of each of the four behavioral
tests and the transcriptome proﬁles of the SAMP8 mouse brains
under balenine (+WME) supplemented diet.
2.2. Behavioral tests on the SAMP8 and SAMR1 mice fed balenine
(+WME)-supplemented diet
To investigate potential balenine (+WME) diet-induced mecha-
nisms underlying effects for learning and memory in SAMP8 as AD
model mouse, we performed four tests. Firstly, mice were evaluated
by open ﬁeld test as measurement of locomotor activity. SAMR1 mice
had signiﬁcantly reduced locomotor activity (SAMR1 LSO; 852.8 ±
60.5). No differences between SAMP8 LSO and SAMP8 WME groups
were observed (SAMP8 LSO; 1520.5 ± 93.9, SAMP8 WME; 1405.7 ±
76.1) (Fig. 2a). Secondly, the Y-maze test results showed that in the
SAMP8 WME group degradation of spatial memory formation signiﬁ-
cantly improved compared to SAMP8 LSO group (SAMR1 LSO; 49.6 ±
4.2, SAMP8 LSO; 41.5 ± 4.0, SAMP8 WME; 56.6 ± 1.8%; p b 0.05)
(Fig. 2b). Thirdly, for the NOR test, there were no differences among
any of the groups (SAMR1 LSO; 65.0 ± 4.9, SAMP8 LSO; 44.9 ± 2.3,
SAMP8WME; 54.4± 4.5%) (Fig. 2c). Fourthly, theWMTM test revealed
that the SAMP8 WME diet group had reduced escape time from the
water in a time-dependent manner, and the observed escape time
was signiﬁcantly different at the 3rd day compared to SAMP8 LSO
group (SAMP8 LSO; 135.9 ± 31.3, SAMP8 WME; 52.5 ± 5.8 2nd,
p b 0.02), but the number of inserted blind array were no different
among any of the groups (Fig. 2d).
2.3. Global gene expression (transcriptomics) analysis of SAMP8 mice fed
with balenine (+WME)-supplemented diet over SAMP8 LSO (−WME)
fed diet
DNA microarray analysis revealed 274 and 224 up (≧1.5-fold)- and
down (≦0.75-fold)-regulated genes in the balenine (+WME)-supple-
mented diet SAMP8 mouse whole brain, interestingly over the much
higher number of genome-wide changes in gene expressions in the
−WME (i.e. LSO diet only) SAMP8 mouse, where 904 and 613 up
(≧1.5-fold)- and down (≦0.75-fold)-regulated geneswere being altered
(Fig. 3). It can also be said that the gene abnormalities (i.e. changed gene
expressions) seen in the SAMP8 model mice brains are being strongly
affected by the balenine (+WME) supplementation. As to what is the
nature of these gene expressions was the next question, we answer
below. These genes are listed in Online Resource 2 (+WME, up- and
down-regulated gene lists) and Online Resource 3 (−WME (LSO), up-
and down-regulated gene lists). These results provide not only the
ﬁrst inventory ofWME supplementeddiet-inﬂuenced genes (seeOnline
Resource 2) in the animal (mouse) brain but also a comprehensive list
of gene expressions in a mousemodel of AD, i.e. SAMP8 (see Online Re-
source 3). To note, log transformed fold (log2 fold) change is used to
represent the expression levels [14]. The reason for using ≧/≦1.5/0.75-
fold as the cut-off value in the present experiment was to consider
Fig. 1. The experimental strategy for investigating the effects of balenine (+WME) supplementation diet in the senescence-accelerated mouse prone 8 (SAMP8) mouse. 24-weeks-old
SAMP8 and senescence-accelerated mouse resistant 1 (SAMR1) mice were housed in individual cages till 50-weeks-old. Following the chow (CE-2) for 24 weeks, mice were fed low-
safﬂower oil (LSO) diet as control diet or balenine through whale meat extract (WME) diet powders until sacriﬁced for 26 weeks. Two analyses were performed, four behavior tests
for learning and memory followed by whole-genome DNA microarray experiment using whole brain in conjunction with bioinformatics analysis. Details are in the text.
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stream bioinformatics analyses. Moreover, as our experiment utilizes
the two-color dye-swap approach (see below, Section 4.5) a highly con-
ﬁdent (severe selection) differentially expressed gene list was generat-
ed in the analysis.
2.4. Comparative analysis of the genes oppositely regulated in the SAMP8
mice fed the balenine (+WME)-supplemented diet and their role in cellu-
lar energy metabolism
The above DNA microarray analysis data also revealed 92 genes ex-
pressions which were recovered in the SAMP8 (+WME) mouse brain
over the same genes expression status in the SAMP8 LSO (−WME)
mouse brain. The color codes (red, up-regulated; green, down-regulat-
ed) mark these genes in Table 1. Each gene recovery, either up-
expressed or down-expressed, is indicated by their ratios. Looking at
the genes expressions oppositely regulated by the diets (+WME or
LSO), and their functions in major metabolic pathways in the cell,
some major trends were noticed in possible modulations of the energy
metabolism via the tricarboxylic acid (TCA) cycle. Some of these genes
(Slc2a5, Treh, Fbp1, Aldob, Ppp1r1a, DNase1, Agxt2l1, Cyp2e1, Acsm1 and
Acsm2, and Pah) expressions are mentioned in a schematic pathway re-
volving around the said metabolic pathways depicting their up- or
down-regulations status, in Fig. 4.
2.5. Functional categorization and IPA analyses of differentially expressed
brain genes of SAMP8mice fed with balenine (+WME)-supplemented diet
and SAMP8 LSO (−WME) fed diet
The functionally categorized genes post-analysis using the
SABiosciences PCR array list (Qiagen) are presented as color coded up-regulated (red) anddown-regulated (green) genes numbers, for each cat-
egory in both the SAMP8 (+WME) and SAMP8 LSO (−WME) mouse
brain (see Online Resource 4). At a glance the number of genes and
gene categories highly expressing in the SAMP8 mouse brain under
control (LSO) diet were reversed in the balenine (+WME)-fed SAMP8
mouse brain (see also, Table 1). For a wider bioinformatics analysis, a
biological function and network analysis was performed using the IPA
tool generating numerous networks and pathways revealing the balenine
(+WME)-supplemented diet affecting the SAMP8 mouse brain in
complex ways (see Online Resources 5 and 6). Each sample condition
IPA analysis also provided us with a list of top molecules that are
gene candidates for the potential mechanism/s underlying the
balenine (+WME)-supplemented diet effects in the SAMP8 model
mouse (Fig. 5).
3. Discussion
Our study indicates that the balenine (+WME)-supplemented diet
has ﬁrst, brought about a change in the behavior of the SAMP8 mice,
namely, the improvement in the learning and memory formation, and
secondly, caused numerous positive genome-wide changes in the
brain of SAMP8 mouse over the LSO diet (control)-fed mouse. Inadver-
tently, these genomic data also revealed that the SAMP8 (AD model)
mouse-fed LSO (−WME) had more numbers of changed gene expres-
sions (1517 genes) than the SAMP8 mouse-fed (+WME) diet (498
genes) (Fig. 3). This can be expected as the SAMP8 is an AD model
mice [11,12]. Interestingly many genes known to be affected in AD
were also found to be present among these differentially expressed
genes and when comparing the SAMP8 brains to the SAMR1 brains
(seealso Table 1 and Fig. 5). We discuss some of these genes below in
context of the recovery of gene expressions in the brain following the
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Fig. 2. The four behavioral tests for examining the balenine (+WME)-supplementeddiet or not (LSO) effects in the SAMP8mouse.Weperformedopen ﬁeld test (a), Y-maze test (b), novel
object recognition test (NOR; c), andwater-ﬁlledmultiple T-maze test (WMTM; d). (a) Locomotor activity of SAMR1micewere signiﬁcantly decreased compared to SAMP8 LSO andWME
groupmice. However, no signiﬁcant differences were observed between SAMP8 LSO group and balenine (+WME) group. (b) In the evaluation of learning impairment using Y-maze test,
the SAMP8WME group showed a signiﬁcant alteration in behavior compared to the SAMP8 LSO group. No differences were seen between SAMP8 (+WME) and SAMR1 LSO groups (one-
way comparison post-hoc test; *p b 0.05). (c) In the training for novel object recognition, ﬁrst during the training period two objects (A and A′) were presented to amouse. Second, during
the testingphase, one of the conditioned objectswas replacedby a differently colored novel object (A andB). During training allmice groupswere found to equally touch the objects (A and
A′). During testing, SAMR1 LSO and SAMP8 (+WME) groups increased the percentage of touching novel objects, however there were no differences among groups. (d) In the escape
latency from multiple T-maze in water maze, the SAMP8 (+WME) group showed a signiﬁcantly faster escape latency on day 3 compared to SAMP8 LSO group (repeated measures
one-way ANOVA, Bonferroni's multiple comparison tests; #p b 0.02). LSO: low-safﬂower oil.
41N. Wada et al. / Genomics Data 10 (2016) 38–50feeding of mouse with the balenine (+WME)-experimental diet over
the control diet (LSO,−WME). The present study thus provides genes
and their potential roles/functions in context of the utilization of the
balenine as a possible supplement for human wellness, especially in
regards to the AD model used in this study.
In the behavioral part of this study, SAMP8 balenine (+WME)-diet
group showed signiﬁcantly differences compared to SAMP8 LSO diet
(control) group in Y-maze and WMTM tests. Two previous reports
have shown that WME-induced the anti-fatigue effect in mouse and
human [8,9], concluding that balenine as imidazole dipeptide [4–6] in
the WME might affect the muscle endurance. Searching the literature
we found that another imidazole dipeptide, carnosine, has been report-
ed to have protective effects from ischemic vascular dementia [15], and
that dietary supplementation of carnosine suppressed the accumulation
amyloid-β in hippocampal region in 3 × Tg-AD mice as an AD model
[16]. The chicken breastmeat is known to abundantly contain carnosine
[17]. That balenine is abundantly and speciﬁcally present in whalemeat
has also been reported [18], but there is no study to our knowledge on
its (balenine) phygiological role. However, based on previous re-
searches and our preliminary data (see Online Resource 1), we have
considered the present study whereby, the results suggest an improve-
ment in learning and memory function (Fig. 2) in SAMP8 balenine(+WME)-fed supplemented diet mice. Our results also lead us to spec-
ulate that baleninemay exert a similar function as the imidazole dipep-
tide carnosine [19]. This may include possible roles as activators of the
enzyme adenosine triphosphate, formation of energy-rich phosphorus
compounds, buffers (protective action on themitochondrial structures),
as have been discussed for anserine and carnosine, mostly in themuscle
[19]. This however needs to thoroughly examined in the mouse brain
and proved in the future studies. As will be discussed below, the
balenine (+WME)-supplemented diet is seen to cause, in the brain of
the SAMP8 mouse, a recovery in the energy requirements or balance
of the brain power via providing energy substrates and critical amino
acids, including the non-essential amono acid beta-alanine (Fig. 4),
that could be directly derived from balenine, in the WME degradation.
Table 1 lists the genes (92) oppositely regulated/recovered by the
balenine (+WME)-supplemented diet. These genes present insight
into the positive effects of the balenine-rich (WME) diet on the
SAMP8 mouse, which we ﬁnd to be impaired in metabolic functions as
exempliﬁed by the plotting of these genes on the energy metabolism
pathway/s shown in Fig. 4. Though speculative at this stage, this DNA
microarray-based gene expression data and analysis points twoards
the fact that the balenine (WME) diet might exert a positive effect on
the glucose and gluconeogenesis, ethanol fermenation, fatty acid
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way), aromatic amino acids, and ﬁnally the TCA cycle. In other words,
it implies that balenine (+WME)-supplemented diet might provide
the necessary energy resources impaired in the SAMP8 mouse to pro-
vide the brainwith necessarymetabolites and amino acids for its proper
functioning. Here, in relation to the above mentioned balenine
(+WME) positively affecting learning and memory functions in the
SAMP8mice and the glucosemetabolism pathway genes being affected
genome-wide, we would like to mention some previous literature
pointing to a link between learning memory and glucose metabolism
in aging brain and in causes of disorders causing dementia [20–25].
For example, a study by Mayer and co-workers (1990) inducing irre-
versible hyperglycemia and depression of cerebral glucose metabolism
via the intracerebroventricular (i.c.v.) or intraperitoneal (i.p.) adminis-
tration of streptozotocin (STZ), which is known to damage insulin-pro-
ducing cells, examined the behavioral functions (locomotor activity,
learning andmemory) in rat [24]. Results revealed that the STZ-i.c.v. in-
jection ratwas impaired in learning tasks comparedwith control groups
and the STZ-i.p. injection group, suggesting impairment of passive
avoidance learning might reﬂect a poorer acquisition and/or retention
of memory in these rats [24]. This lead those authors to further suggest
that poor cerebral regulation of glucose would be a primary metabolic
event involved in impairments of learning and memory [24]. In 2003,
Hoyer summarized studies speciﬁcally focused on the role of cerebral
glucose metabolism and the function of insulin in the brain regarding
memory capacity under normal and pathological conditions, including
AD [25,26]. An interesting result to mention from that paper is the ﬁnd-
ing that Ginkgo biloba extract (EGb 761®) exerts a beneﬁcial effect on
STZ-damaged rats returning them to completely normal values ofcerebral energy metabolism, including partial compensation of the def-
icits in learning, memory and cognitive ability [25]. Indirectly, these
data provide support to the beneﬁcial effects of balenine (+WME)
diet on abnormalities in behavior and possible link to the recovery of
the energy metabolism in the SAMP8 mouse model.
In the following paragraphs, we discuss some of these genes pre-
sented in Table 1, ﬁrst taking an example of the glucose metabolism/
transport-related Slc2a5 gene. Slc2a5, which is a solute carrier family 2
(facilitated glucose transporter) member 5 (Glut5), is down-expressed
in balenine(+WME) over the LSO (−WME) diet. Although several of
the GLUTs have been identiﬁed in the brain, it is GLUT1, which is the
key transporter of glucose through the blood brain barrier [27]. The
GLUT 5 (Glut5/Slc2a5), known as a fructose transporter having very
low afﬁnity for glucose, has been shown to be expressed in human
and rat microglia cells but its functional signiﬁcance remains unknown
[27,28]. Although glucose metabolism alterations have been suggested
to play a role in AD, the mechanism remains unclear as also the link to
AD [27]. Nevertheless, altered brain glucose levels and metabolism are
suggested to be impaired in neurodegenerative diseases, and this
might be the case with the SAMP8 model. Therein, we come across
the second gene, namely Treh [29], which conversely to Slc2a5 is highly
expressed in the balenine(+WME) condition. This implies the
TREHALASE, catalyzing the hydrolysis of trehalose into glucose provid-
ing an alternative source of energy [30,31], is available in the balenine
(+WME) SAMP8 mouse and might be utilized for the production of
glucose, based on the Treh gene expression level. It is also interesting
to note that this implies an additional availability of trehalose, and
which if might be proven in later studies, would be important factor
in the improved learning and memory we ﬁnd in the SAMP8
(+WME) mice. The reason may lie in the fact that this disaccharide is
also known as an antioxidant protecting cells from injury, suppressing
protein aggregation including having cellular and behavioral beneﬁcial
effects in animal models of neurodegenerative disorders [32].
These results lead us to speculate on the availability of glucose in the
SAMP8 mice fed the balenine (+WME)-supplemented diet, which
might help in recovering the said glucose deﬁciency in thesemice. Sim-
ilarly, we see the increased up-expression of the Fbp1 (fructose-1,6-
bisphosphate 1) and Aldob (aldolase B, fructose-bisphosphate) genes
in the (+WME) SAMP8 mouse, again pointing towards activated gly-
colysis pathway, and leading to the TCA cycle. The other signiﬁcant
genes positively regulated by the balenine (+WME) supplemented
diet in SAMP8 mouse were, alanine-glyoxylate aminotransferase 2-
like 1 (Agxt2l1; glutamate catabolism, promoting the conversion of L-
alanine + glyoxylate to pyruvate + glycine, metabolism of L-gluta-
mate), cytochrome P450, family 2, subfamily e, polypeptide 1 (Cyp2e1;
conversion of ethanol to acetaldehyde), acyl-CoA synthetase medium-
chain family member 1 and 2 (Acsm1, Acsm2; priming or activation of
the fatty acids by forming fatty acyl-CoA thioesters), phenylalanine hy-
droxylase (Pah; tetrahydrobiopterin (BH4)-dependent enzyme phenyl-
alanine 4-hydroxylase converts phenylalanine to tyrosine), and
deoxyribonuclease 1 (DNase1; nucleates to ribose-5-P) (Fig. 4). Further,
than their generally known functions, these genes are suggested here, in
this study, to act also for the production of substrates to be utilized for
the energy metabolism in the mitochondria as shown in Fig. 4.
Other than the possibility of the above genes presented in Fig. 4, to-
wards improved energy metabolism in the (+WME) SAMP8 mouse
brain, we would also like to discuss some unique characteristics of
these gene products in relation to disease, speciﬁcally neurodegenera-
tive disorders. The case of the novel gene up-expressed, Agxt2l1, a
class II aminotransferase [33] is presented. First, the AGXT2L1 is a
brain enzyme which might be involved in the pathogenesis of severe
neuropsychiatric disturbances, and second, despite it being a transami-
nasewas recently shown to have a stronger lyase activity (phospholipid
metabolism) than an aminotransferase in human [34]. Taking the case
of the human study, AGXT2L1 acts on O-phosphoethanolamine (PEA)
irreversibly degrading it to acetaldehyde, phosphate and ammonia
Table 1
Genes oppositely regulated in the SAMP8mouse fed the balenine (+WME)-supplement-
ed diet. Color codes (red, up-expressed; green, down-expressed) mark the genes expres-
sions recovering in the SAMP8 balenine (+WME) mouse brain over the same genes
expression state in the SAMP8 LSO (−WME) mouse brain. The genes differentially
expressed in the SAMP8 mice brain (LSO diet) were determined using SAMR1 mice
brain(LSO diet) gene expression data as a reference. LSO, Low-safﬂower oil.
Gene Count(s):   92 genes
SAMP8 
LSO/ 
SAMR1 
LSO
SAMP8 
+WME/  
SAMP8 
LSO
Symbol Description
Ratio 
(average)
Ratio 
(average)
Igk–V19–14
gb|Mus musculus anti–DNA light chain 
(Vk19) mRNA, partial cds. [U59155]
3.91 –3.84 
Igkv6–17
ens|Ig kappa chain V–V region MPC11 
Precursor  
[Source:UniProtKB/Swiss–Prot;Acc:P01633] 
[ENSMUST00000103391]
2.32 –0.84 
ENSMUST00000008011
ens|predicted gene 9946 Gene 
[Source:MGI Symbol;Acc:MGI:3643134] 
[ENSMUST00000008011]
2.04 –0.90 
Cyp2g1
ref|Mus musculus cytochrome P450, 
family 2, subfamily g, polypeptide 1 
(Cyp2g1), mRNA [NM_013809]
1.95 –1.64 
Cyp2a5
ref|Mus musculus cytochrome P450, 
family 2, subfamily a, polypeptide 5 
(Cyp2a5), mRNA [NM_007812]
1.80 –0.87 
Cyp2a4
ref|Mus musculus cytochrome P450, 
family 2, subfamily a, polypeptide 4 
(Cyp2a4), mRNA [NM_009997]
1.78 –0.81 
Rya3
ref|Mus musculus antimicrobial peptide 
RYA3 (Rya3), mRNA [NM_194357]
1.78 –1.89 
Cyp2f2 ref|Mus musculus cytochrome P450, 1.74 –0.70 
family 2, subfamily f, polypeptide 2 
(Cyp2f2), mRNA [NM_007817]
ENSMUST00000108834
ens|RIKEN cDNA 4930438A08 gene Gene 
[Source:MGI Symbol;Acc:MGI:1921238] 
[ENSMUST00000108834]
1.73 –0.97 
ENSMUST00000103746
ens|immunoglobulin lambda chain, 
variable 1 Gene [Source:MGI 
Symbol;Acc:MGI:96530] 
[ENSMUST00000103746]
1.70 –0.63 
Igh–VJ558
ens|Ig alpha chain C region  
[Source:UniProtKB/Swiss–Prot;Acc:P01878] 
[ENSMUST00000103412]
1.66 –1.00 
Gbp1
ref|Mus musculus guanylate binding 
protein 1 (Gbp1), mRNA [NM_010259]
1.56 –0.55 
Lcn2
ref|Mus musculus lipocalin 2 (Lcn2), mRNA 
[NM_008491]
1.55 –0.62 
S100a8
ref|Mus musculus S100 calcium binding 
protein A8 (calgranulin A) (S100a8), mRNA 
[NM_013650]
1.54 –1.32 
Fgf21
ref|Mus musculus fibroblast growth factor 
21 (Fgf21), mRNA [NM_020013]
1.53 –1.93 
Cyp2g1
ref|Mus musculus cytochrome P450, 
family 2, subfamily g, polypeptide 1 
(Cyp2g1), mRNA [NM_013809]
1.51 –1.62 
Scgb1c1
ref|Mus musculus secretoglobin, family 
1C, member 1 (Scgb1c1), mRNA 
[NM_001099742]
1.45 –1.82 
Ugt2a1
ref|Mus musculusUDP 
glucuronosyltransferase 2 family, 
polypeptide A1 (Ugt2a1), mRNA 
[NM_053184]
1.45 –1.23 
Camp
ref|Mus musculuscathelicidin 
antimicrobial peptide (Camp), mRNA 
1.41 –1.41 
[NM_009921]
S100a9
ref|Mus musculus S100 calcium binding 
protein A9 (calgranulin B) (S100a9), mRNA 
[NM_009114]
1.40 –1.26 
AK087643
gb|Mus musculus2 days pregnant adult 
female oviduct cDNA, RIKEN full–length 
enriched library, clone:E230031M10 
product:novel transcript associated with 
phospholipase A2, group IB, pancreas, 
receptor, full insert sequence. [AK087643]
1.34 –0.68
Ltf
ref|Mus musculus lactotransferrin (Ltf), 
mRNA [NM_008522]
1.29 –1.21 
Egr2
ref|Mus musculus early growth response 2 
(Egr2), mRNA [NM_010118]
1.27 –0.72 
Egr2
ref|Mus musculus early growth response 2 
(Egr2), mRNA [NM_010118]
1.26 –0.75 
Egr2
ref|Mus musculus early growth response 2 
(Egr2), mRNA [NM_010118]
1.24 –0.74 
Egr2
ref|Mus musculus early growth response 2  
(Egr2), mRNA [NM_010118]
1.24 –0.75 
Egr2
ref|Mus musculus early growth response 2 
(Egr2), mRNA [NM_010118]
1.23 –0.73 
Egr2
ref|Mus musculus early growth response 2 
(Egr2), mRNA [NM_010118]
1.22 –0.74 
Egr2
ref|Mus musculus early growth response 2 
(Egr2), mRNA [NM_010118]
1.22 –0.73 
Egr2
ref|Mus musculus early growth response 2 
(Egr2), mRNA [NM_010118]
1.20 –0.71 
Egr2
ref|Mus musculus early growth response 2 
(Egr2), mRNA [NM_010118]
1.20 –0.73 
Egr2
ref|Mus musculus early growth response 2 
(Egr2), mRNA [NM_010118]
1.20 –0.74 
Fos ref|Mus musculus FBJ osteosarcoma 1.15 –0.94 
oncogene (Fos), mRNA [NM_010234]
Fos
ref|Mus musculus FBJ osteosarcoma 
oncogene (Fos), mRNA [NM_010234]
1.14 –0.97 
Fos
ref|Mus musculus FBJ osteosarcoma 
oncogene (Fos), mRNA [NM_010234]
1.14 –0.95 
AK143879
gb|Mus musculus 6 days neonate spleen 
cDNA, RIKEN full–length enriched library, 
clone:F430214N12 product:unclassifiable, 
full insert sequence. [AK143879]
1.14 –0.74 
Fos
ref|Mus musculus FBJ osteosarcoma 
oncogene (Fos), mRNA [NM_010234]
1.14 –0.95 
Fos
ref|Mus musculus FBJ osteosarcoma 
oncogene (Fos), mRNA [NM_010234]
1.13 –0.95 
Fos
ref|Mus musculus FBJ osteosarcoma 
oncogene (Fos), mRNA [NM_010234]
1.13 –0.95 
Mmp13
ref|Mus musculus matrix 
metallopeptidase 13 (Mmp13), mRNA 
[NM_008607]
1.13 –0.80 
Fos
ref|Mus musculus FBJ osteosarcoma 
oncogene (Fos), mRNA [NM_010234]
1.12 –0.96 
Fos
ref|Mus musculus FBJ osteosarcoma 
oncogene (Fos), mRNA [NM_010234]
1.11 –0.96 
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Igh–VJ558
ens|Ig alpha chain C region  
[Source:UniProtKB/Swiss–Prot;Acc:P01878] 
[ENSMUST00000103412]
1.11 –0.72 
Fos
ref|Mus musculus FBJ osteosarcoma 
oncogene (Fos), mRNA [NM_010234]
1.09 –0.92 
Fos
ref|Mus musculus FBJ osteosarcoma 
oncogene (Fos), mRNA [NM_010234]
1.09 –0.95 
Igh–VJ558
ens|Ig alpha chain C region  
[Source:UniProtKB/Swiss–Prot;Acc:P01878] 
[ENSMUST00000103412]
1.08 –0.62 
Ngp ref|Mus musculus neutrophilic granule 1.02 –1.55 
protein (Ngp), mRNA [NM_008694]
Nr4a1
ref| Mus musculus nuclear receptor 
subfamily 4, group A, member 1 (Nr4a1), 
mRNA [NM_010444]
1.01 –0.67 
Ear10
ref|Mus musculus eosinophil–associated, 
ribonuclease A family, member 10 (Ear10), 
mRNA [NM_053112]
0.95 –1.36 
Ppbp (=CXCL7)
ref|Mus musculus pro–platelet basic 
protein (Ppbp), mRNA [NM_023785]
0.90 –0.77 
Ddx58
ref|Mus musculus DEAD (Asp–Glu–Ala–Asp) 
box polypeptide 58 (Ddx58), mRNA 
[NM_172689]
0.90 –0.73 
Scn9a (=Nav1.7)
ref|Mus musculus sodium channel, 
voltage–gated, type IX, alpha (Scn9a), 
mRNA [NM_018852]
0.78 –0.63 
Nr4a3
ref|Mus musculus nuclear receptor 
subfamily 4, group A, member 3 (Nr4a3), 
mRNA [NM_015743]
0.74 –0.72 
Ltf
ref|Mus musculus lactotransferrin (Ltf), 
mRNA [NM_008522]
0.74 –0.92 
Retnlg
ref|Mus musculus resistin like gamma 
(Retnlg), mRNA [NM_181596]
0.68 –0.81 
Hsd17b12
gb|Mus musculus 10, 11 days embryo 
whole body cDNA, RIKEN full–length 
enriched library, clone:2810004A21 
product:hydroxysteroid (17–beta) 
dehydrogenase 12, full insert sequence. 
[AK076088]
0.53 –0.59 
1600017P15Rik
gb|Mus musculus adult female placenta 
cDNA, RIKEN full–length enriched library, 
clone:1600017P15 product:unclassifiable, 
full insert sequence. [AK005488]
–0.54 0.63 
Mettl7b ref|Mus musculus methyltransferase like –0.69 1.01 
7B (Mettl7b), mRNA [NM_027853]
ENSMUST00000112652
gb|Mus musculus 16 days neonate heart 
cDNA, RIKEN full–length enriched library, 
clone:D830032D10 product:unclassifiable, 
full insert sequence. [AK085942]
–0.75 0.80 
Aldob
ref|Mus musculus aldolase B, 
fructose–bisphosphate (Aldob), mRNA 
[NM_144903]
–0.76 1.76 
gb|Mus musculus adult male pituitary 
gland cDNA, RIKEN full–length enriched 
library, clone:5330407B06 product:weakly 
Table 1. (continued)
Agxt2l1 similar to ALANINE:GLYOXYLATE 
AMINOTRANSFERASE 2 HOMOLOG 1, 
SPLICE FORM 1 [Homo sapiens], full insert 
sequence. [AK030395]
–0.76 0.60 
Treh
ref|Mus musculustrehalase (brush–border 
membrane glycoprotein) (Treh), mRNA 
[NM_021481]
–0.78 1.30 
Clec2h
ref|Mus musculus C–type lectin domain 
family 2, member h (Clec2h), mRNA 
[NM_053165]
–0.78 0.96 
Fbp1
ref|Mus musculus fructose 
bisphosphatase 1 (Fbp1), mRNA 
[NM_019395]
–0.78 1.93 
Aldob
ref|Mus musculus aldolase B, 
fructose–bisphosphate (Aldob), mRNA 
[NM_144903]
–0.80 1.77 
Defa–rs12
ref|Mus musculus defensin, alpha, related 
sequence 12 (Defa–rs12), mRNA 
[NM_007846]
–0.84 1.18 
Tmem27
ref|Mus musculus transmembrane protein 
27 (Tmem27), mRNA [NM_020626]
–0.86 2.09 
AU018778 ref|Mus musculus expressed sequence –0.87 2.87 
AU018778 (AU018778), mRNA 
[NM_144930]
ENSMUST00000060246
ens|RIKEN cDNA 1110008E08 gene Gene 
[Source:MGI Symbol;Acc:MGI:1915750] 
[ENSMUST00000060246]
–0.93 0.89 
2810405F15Rik
ref|Mus musculus RIKEN cDNA 
2810405F15 gene (2810405F15Rik), 
non–coding RNA [NR_033447]
–0.95 0.65 
Aldob
ref|Mus musculus aldolase B, 
fructose–bisphosphate (Aldob), mRNA 
[NM_144903]
–0.96 2.09 
Fxyd2
ref|Mus musculus FXYD 
domain–containing ion transport regulator 
2 (Fxyd2), transcript variant b, mRNA 
[NM_052823]
–0.97 1.91 
Gtpbp8
gb|Mus musculus adult retina cDNA, 
RIKEN full–length enriched library, 
clone:A930006C13 product:unclassifiable, 
full insert sequence. [AK044298]
–0.97 0.98 
TC1676807
tc|Q6NS85_MOUSE (Q6NS85) Sgk protein, 
partial (45%) [TC1676807]
–1.05 0.96 
Pah
ref|Mus musculus phenylalanine 
hydroxylase (Pah), mRNA [NM_008777]
–1.05 2.10 
Smchd1
gb|Mus musculus 0 day neonate eyeball 
cDNA, RIKEN full–length enriched library, 
clone:E130019A11 product:unclassifiable, 
full insert sequence. [AK053453]
–1.06 0.64 
Acsm2
ref|Mus musculusacyl–CoA synthetase 
medium–chain family member 2 (Acsm2), 
nuclear gene encoding mitochondrial 
protein, transcript variant 3, mRNA 
[NM_146197]
–1.07 3.81 
S100g ref|Mus musculus S100 calcium binding –1.10 3.57 
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protein G (S100g), mRNA [NM_009789]
Cyp4b1
ref|Mus musculus cytochrome P450, 
family 4, subfamily b, polypeptide 1 
(Cyp4b1), mRNA [NM_007823]
–1.14 2.46 
Fam83d
ref|Mus musculus family with sequence 
similarity 83, member D (Fam83d), mRNA 
[NM_027975]
–1.19 0.61 
Slc17a3
ref|Mus musculus solute carrier family 17 
(sodium phosphate), member 3 (Slc17a3), 
transcript variant 1, mRNA [NM_134069]
–1.32 2.54 
Keg1
ref|Mus musculus kidney expressed gene 
1 (Keg1), mRNA [NM_029550]
–1.53 3.52 
Pdzd2
gb|Mus musculus 0 day neonate eyeball 
cDNA, RIKEN full–length enriched library, 
clone:E130016M22 product:unclassifiable, 
full insert sequence. [AK087419]
–1.61 0.59 
Slc34a1
ref|Mus musculussolute carrier family 34 
(sodium phosphate), member 1 (Slc34a1), 
mRNA [NM_011392]
–1.63 3.22 
B430316J06Rik
gb|Mus musculus 4 days neonate male 
adipose cDNA, RIKEN full–length enriched 
library, clone:B430316J06 
product:unclassifiable, full insert 
sequence. [AK046698]
–1.76 1.58 
Cyp2j5
ref|Mus musculus cytochrome P450, 
family 2, subfamily j, polypeptide 5 
(Cyp2j5), mRNA [NM_010007]
–1.84 4.17 
Acsm1
ref|Mus musculusacyl–CoA synthetase 
medium–chain family member 1 (Acsm1), 
mRNA [NM_054094]
–1.93 4.34 
Cyp2e1
ref|Mus musculus cytochrome P450, 
family 2, subfamily e, polypeptide 1 
(Cyp2e1), mRNA [NM_021282]
–2.05 3.30 
Cyp2j5
ref|Mus musculuscytochrome P450, 
family 2, subfamily j, polypeptide 5 
(Cyp2j5), mRNA [NM_010007]
–2.48 4.70 
Dnase1
ref|Mus musculusdeoxyribonuclease I 
(Dnase1), mRNA [NM_010061]
–2.50 4.40 
Acsm2(ACSM2B)
ref|Mus musculusacyl–CoA synthetase 
medium–chain family member 2 (Acsm2), 
nuclear gene encoding mitochondrial 
protein, transcript variant 3, mRNA 
[NM_146197]
–3.13 4.15 
Kap
ref|Mus musculus kidney androgen 
regulated protein (Kap), mRNA 
[NM_010594]
–4.06 5.94 
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“PEA is both a byproduct of sphingolipid degradation and a precursor of
glycerophospholipid biosynthesis and it can accumulate when mem-
brane remodeling or degradation increase”; such an accumulation can
lead to mitochondrial dysfunction [35]. Thus, AGXT2L1 might act as a
protector of the toxic metabolite increase in cells or in the case of dis-
ease might serve as a compensatory mechanism to alleviate the effects
of excessive membrane degradation [34]; is this the case in the SAMP8
mouse brain, though we do not know at present. The Agxt2l1 gene
was also recently shown to be one of the three strongly up-regulated
brain genes in the mouse model of psychiatric disorders/neurologicaldiseases, such as compound C and lithium therapy, which have been
used to study the effects on chromatin-modifying enzymes such as the
histone deacetylase [36]. These data suggest an involvement of the
Agxt2l1 gene in AD, though it should be noted that this gene function
needs further investigation and validation as a novel target of lithium
and neuroleptics, thus providing greater relevance to its decreases in
depression and suicide and increases in bipolar disorder and schizo-
phrenia [37].
Another exciting ﬁnding of an up-expressed gene is Pah, which, in-
terestingly, causes a reduction in the amino acid phenylalanine turnover
in chronic inﬂammation conditions that is known to affect dopamine,
adrenaline and noradrenaline synthesis, as tyrosine is the precursor of
these neurotransmitters [38]. Moreover, a cross-regulation between
the immune response and severe metabolic changes is known and
a connection therein with depression and cognitive impairment,
which is in turn linked with changes in amino acid metabolism and
neurotransmitter (serotonin, L-DOPA, dopamine, noradrenaline
and adrenaline) synthesis [38–41]. As recently reported by Gostner
and co-workers (2015), the low-inﬂammatory stress-associated
dysregulation of amino acid metabolism may be part of the patho-
physiology of common HIV-associated neuropsychiatric conditions
[38]. These reports led us to speculate that SAMP8 mice model of
AD brains might have an amino acid imbalance and that is being
possibly recovered in part by the up-expression of genes, such as
Pah, with the balenine (+WME)-supplemented diet. Herein, again
the role of balenine (in the WME) may be called to question and
further investigation.
From the functional gene categories, the gene numbers in antifungal
response, NFκB signaling targets, cancer inﬂammation and immunity
crosstalk, inﬂammatory responses and autoimmunity related categories
were highly dominant in the SAMP8 mouse (LSO diet) brain. Contrast-
ingly, these functional categeories were considerably reduced in gene
numbers in the SAMP8 mouse-fed balenine (+WME) diet, brain (see
Online Resource 3). Looking carefully at the literature it was found
that brain infections have recently become an important topic in rela-
tion to AD [42–44]. A most recent publication showed that different
brain regions (central nervous system) of AD patients are infected
with fungal pathogens [45]. However, as those authors mention, it is
not clear as towhether the fungal agentswere the cause of AD or the pa-
tients, who were elderly, had a poor adaptive immune response
resulting in them having fungal infections [45]. As also recently report-
ed, researchers have considered the idea that ADmight be an infectious
disease or that infectious agents, include bacteria are risk factors for AD
[46,47]. The gene category for antibacterial response was also dominant
in the SAMP8 (LSO diet) mouse brain (see Online Resource 3). Neuroin-
ﬂammation or the inﬂammatory processes also are thought to play an
important part in the pathogenesis of AD [48–50], and these gene cate-
gories are also well represented in the SAMP8 (LSO diet) mouse brain
(see Online Resource 3).
Combining the powerful approach of DNA microarray chip technol-
ogywith the IPA bioinformatic tool, the possible brain gene interactions
and pathways/networks could be delineated. These networks, one
through six, for both SAMP8 mouse-fed balenine (WME) and LSO
diets are shown inOnline Resources 5 and 6. The topmolecules present-
ed in Fig. 5, of which some can also be seen in the Table 1 (oppositely
regulated expressions in the balenine+WMEmouse-fed diet), suggest
their importance as key genes in the said positive effects of balenine
(+WME) supplementation. It would be interesting to analyze these
genes (Kap, Cyp2j5, S100G, Keg1, UGT2B28, Igkv6-14, HLA-A, CCL19,
etc.) individually and further bioinformatics analysis would shed light
on their possible role/function and modulation by balenine (+WME)-
supplemented diet in the SAMP8 mouse. For example, the most highly
up-regulated and top molecule (Fig. 5), namely, Kap gene that was
also the most down-regulated gene in SAMP8 mouse-fed LSO diet
showed a dramatic recovery in its expression with the balenine
(+WME) diet (Table 1). Kap encodes for the kidney androgen-
Fig. 4. The genes of themajor cellularmetabolic pathways inﬂuenced in thewhole brain of SAMP8mousewith orwithout balenine (WME) supplementation. The red andblue bold arrows
indicate up-regulated and down-regulated expression of genes (italicized) located intermediate to the respective substrates and products. Balenine (+WME) indicates SAMP8 mice fed
with the experimental diet containing balenine as described in the Materials and methods section.−WME refers to the SAMP8 mice fed the control diet (LSO, low-safﬂower oil).
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being widely investigated but nothing is known about it in the brain.
Kap expression and presence raises new questions about its possible
role in the brain of the SAMP8 mouse.
In summary, this research is a ﬁrst such study describing the effects
of balenine (inWME) as a dietry supplement in a mice model (SAMP8)
using both behavioral tests and high-throught DNA microarray-based
omics approach, which provides new insight into the effects of the
meat supplemented diet on the AD model mouse brain. To note, a pre-
vious study has also investigated the aging-related gene expression pro-
ﬁles in the frontal cortext of SAMP8 [52]. In particular, the energy
metabolism pathways discussed above and amino acids provision to
the brain point towards the beneﬁcial positive effects of balenine
(+WME) diet on the SAMP8 mouse, which are interesting but require
further experimental evidence. Our study helps set up a model system
to investigate further the effects of speciﬁc whale meat compoments,
such as the imidazole dipeptide balenine, and most probably othernatural meats/products for possible beneﬁcial effects on the human
body. In addition, the obtained gene information resource in this study
might serve well in investigating and designing new therapies that tar-
get these genes/proteins/enzymes of the said metabolic pathways for
AD. The upcoming studies in our group will not only look directly at
the effects of balenine in animal models of AD (SAMP8)/neurological
diseases, but also utlize other omics-based approaches, proteomics
[53] and metabolomics to try link the genes from this microarray
analysis to their products for a better understanding of how the
balenine (+WME) supplemented diet affects the observed positive
effects on brain recovery and function in the AD model mouse. We
would argue at the end that this study was conducted only as a test
to try get an insight into the positive effects of the dipeptide balenine
(though dietry supplementation) a major component of the whale
meat that formed/forms the diet of not only ancient, and to some extent
current, Japanese people, but also in otherwhale eating traditions in the
world.
SAMP8 (+WME) SAMP8(-WME) (+LSO)
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Fig. 5. The topmolecules identiﬁed by IPA analysis in thewhole brain of SAMP8mousewith or without balenine (WME) supplementation. Gene names are in blue, and the up- and down-
regulated genes along with the fold changes are indicated by red and green bold arrows for each sample condition. Balenine (+WME) indicates SAMP8 mice fed with the experimental
diet containing balenine as described in the Materials and methods section.−WME refers to the SAMP8 mice fed the control diet (LSO, low-safﬂower oil).
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4.1. Animals and husbandary, supplemented diet, and sampling of whole
brain
Six-weeks-old SAMP8 and SAMR1 mice (CLEA, Tokyo, Japan) were
housed at the Animal Institution Facility in ShowaUniversity, andmain-
tained in individual cages in a ventilated animal room with controlled
temperature and relative humidity under a 12 h light: 12 h dark regime
(8:00AM, lights turned on).Micewere fed chow(CE-2, CLEA Japan) and
tap water ad libitum until 24-weeks-old. Then, 24-weeks-old SAMs
mice were given experimental diets, balenine (+WME)-supplemented
diet and LSO as a control diet, and both in a powder form. TheWMEwas
prepared from red meat of Antarctic minke whale Balaenoptera
bonaerensis taken from the Japanese Whale Research Program under
Special Permit in the Antarctic-Phase II in 2009/2010 by heat, enzyme
and drying treatments, and as provided by Kyodo Senpaku Co. Ltd.,
Tokyo (Japan). The quality standard of whale meat was measured by
Marugei Co. Ltd., (Hyogo, Japan), and results of the analysis are shown
in Online Resource 7. The LSO diet components are shown in Online Re-
source 8. SAMP8 mice were randomly given balenine (in WME) or LSO
diet, respectively. SAMR1 mice were given only the LSO diet, until 50-
weeks-old. The behavioral tests, as detailed below, were performed at
the timing of 49-weeks-old for eight days. At the end of the experiment
(50-weeks of age) following the behavioral analysis and the last day of
the feeding, the mice were removed their cages, decapitated and their
brains carefully removed on ice. The whole brains were quickly frozen
in liquid nitrogen in sterile freeze tubes, and stored at−80 °C, till ex-
traction of total RNA (Online Resource 9) for downstreamDNAmicroar-
ray analysis (see also Sections 4.4. and 4.5.). All animal studies were
conducted in accordance with the “Standards Relating to the Care Man-
agement of Experimental Animals” (Notice No. 6 of the Ofﬁce of PrimeMinister dated March 27, 1980) and with approval from the Animal
Use Committee of Showa University (Approval Number: #04093).
4.2. Behavioral tests
To evaluate the effect of WME on the mouse, behavioral tests were
carried out as follows: open ﬁeld test, Y-maze test, novel object recogni-
tion test (NOR) and water-ﬁlled multiple T-maze (WMTM) [54]. The
number of animals in each test was as follows: SAMP8 LSO, n = 8;
SAMP8 WME, n = 10; SAMR1 LSO, n = 10. Behavioral testing was
performed between 10:00 AM and 6:00 PM. To habituate the animals
to the testing room conditions, micewere transferred to the behavior
testing room 1 h (9:00 AM to 10:00 AM) prior to beginning the ﬁrst
trial. The test roomwas not illuminated by the overhead lights but by
using indirect lighting that pointed upwards to the roof. All apparatus
were purchased from Bio-Research Co. Ltd. (Tokyo, Japan), and
analysis of behavior test were analyzed by the SMART software 2.0
(Bio-Research Co. Ltd.). Each test was performed consequently for
8 days (open ﬁeld test, 1 day; Y-maze test, 1 day; NOR, 2 days;
WMTM, 4 days). We describe below, in detail, each test, and the images
of each of the four apparatus set-up are schematically depicted in
Online Resource 10.
4.2.1. Open ﬁeld test
Miceweremoved to the test room in their home cages andwere han-
dled by the base of their tails at all times. Eachmousewas placed into the
one of the four corners of the open ﬁeld (45 cm × 45 cm × 40 cm) and
allowed to explore the apparatus for 5 min (see Online Resource 10a).
After 5 min, the mouse were returned to its home cage, and the open
ﬁeld was cleaned with oxidative water and permitted to dry between
tests, followed by the second mouse.
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The Y-maze apparatus consisted of three arms made of gray plastic
joined in the middle to form a “Y” shape (see Online Resource 10b).
The walls of the arms were combinated, and the one arm component
spec is 300 × 60 × 150 mm. The mouse was placed into one of the
arms of the maze (start arm) and allowed to explore freely all three
arms of the maze for 8 min. The number and the sequence of arms en-
tered were recorded. The dependent variables were activity, deﬁned
as the number of arms entered, and percent alternation, calculated as
the number of alternations (entries into three different arms consecu-
tively) divided by the total possible alternations.
4.2.3. Novel object recognition test
The NOR test was performed using the open ﬁeld box (see, open
ﬁeld test above) (see Online Resource 10c). Mice were individually ha-
bituated to the apparatus for 10 min at the 1st day (training day). The
mouse can freely explore the open ﬁeld area and touch the novel objects
(A and A′) for 10 min. The animal behavior was recorded and we did a
touch count, i.e., the number of times the mouse touched the objects
was counted. On the next day, mice were individually let into the
open ﬁeld area again. We observed the mouse noticing change in the
color of the object (A and B). If the mouse remembered the color of
the object from the previous day, the tendency of themousemoving to-
wards the novel object is greater. This behavior alteration was recorded
and the number of touches to the novel object was counted. Only 5 min
were given to each mouse on the 2nd day.
4.2.4. Water-ﬁlled multiple T-maze test
TheWMTM test is known as the multiple learning and memory test
[54]. WMTM consists of seven T-maze combinations (20 cm wall
height× 9 cmwidth),which areﬁlledwithwater (22±1 °C) to a height
of 16 cm (see Online Resource 10d). During training (day 1), mice were
habituated to the water by swimming three times a day. Mice remem-
bered the goal position in order to escape from thewater. During testing
(days 2, 3 and 4),micewere placed at the start position in thewater and
allowed to swim freely for amaximumof 180 s.Wemeasuredwhen the
mouse entered into the blind alley or not, and the time taken to arrive at
the goal position. The interval time of this test is 2 h, and we performed
this test three times in a day for three consecutive days.
4.3. Statistical analysis
All statistical analyses were performed with the Sigma Plot 12
(Hulinks, Tokyo, Japan) software package. Differences between three
groups were assessed using the one-way analysis of variance
(ANOVA) followed by Bonferroni's post-hoc test. Values were reported
as the mean ± SE. Statistical signiﬁcance was deﬁned as p b 0.05.
4.4. Total RNA extraction
The deep-frozenwholemouse brain in a freeze tubewas transferred
from the deep freezer to a containerwith liquid nitrogen. The tissuewas
then carefully transferred to a pre-chilled (in liquid nitrogen) mortar
and ground with a pestle to a very ﬁne powder with liquid nitrogen
[55–57]. Sample powders were immediately used for the next step of
total RNA extraction by the QIAGEN RNeasy Mini Kit (QIAGEN, Mary-
land, USA) or stored at−80 °C. Prior to DNA microarray analysis, the
total RNA, quantity and quality measured spectrophotometrically with
NanoDrop (Thermo Scientiﬁc, Wilmington, DE, USA) and re-conﬁrmed
using formaldehyde-agarose gel electrophoresis [55–57]. The obtained
total RNAqualitymeasurements revealed good quality as demonstrated
by theA260/280 values N 1.8, A260/230 N 1.8; in our experiments, aiming for
a higher value of N2.0 to 2.3 [55–57]. Further, we obtained total RNA in
optimum quantity of N300 ng/μl. The total RNA was visualized for
conﬁrming pre-experimental integrity of the total RNA subunits by gel
electrophoresis as shown in Online Resource 9.4.5. DNA microarray chip-based whole genome brain transcriptome
proﬁling
The total RNA that was extracted from the brain tissues for each an-
imalwas pooled in each group (SAMP8 LSO; SAMP8WME; SAMR1 LSO)
prior to DNA microarray analysis. As mentioned in Online Resource 9,
for total RNA extraction individual biological replicates for SAMP8 LSO
(n = 5), SAMP8 +WME (balenine) (n = 4), and SAMR1 LSO
()−WME) (n= 5) were used. These RNAs were pooled for application
to the DNAmicroarray chip for one experiment. In addition, two techni-
cal replicates were performed by using two DNA microarray chips fol-
lowing the two-color dye-swap approach (detailed in Fig. 1). The
reason for pooling the total RNA and not individual tissues is ﬁrst, due
to the usually larger variability at the tissue level than at the RNA level
for estimating the gene expression, and second, in theuse of lesser num-
ber of chips that was an economical/cost-effective option for the highly
expensive microarray analysis [55,58,59]. All the steps followed in se-
quence provided conﬁdence that we had the best quality total RNA for
use in the DNA microarray chip. As a last step, the Agilent mouse
whole genome 4 × 44 K (G4122F) DNA slide (composed of four chips
on one slide) was used for the microarray analysis, which was per-
formed according to the Agilent instructions (Agilent Technologies,
Santa Clara, CA, USA) and detailed in our publications [55–57,60]. Our
established DNA microarray analysis experiment is also based on the
two-color dye-swap approach providing a more-stringent selection
condition for changed gene expression proﬁling than a simple single/
two-color approach [55]. Brieﬂy, total RNA (200 ng) was labeled with
either Cy3 or Cy5 dye using an Agilent Low-RNA-Input Fluorescent Lin-
ear Ampliﬁcation Kit (Agilent Technologies). Fluorescently labeled tar-
gets of control (SAMP8−/SAMR1−) as well as treatment (SAMP8+/
SAMP8−) indicated in Fig. 1 were hybridized to the same microarray
slide with 60-mer probes. A ﬂip-labeling (dye-swap or reverse labeling
with Cy3 and Cy5 dyes) procedurewas followed to nullify dye bias asso-
ciated with unequal incorporation of the two Cy dyes into cDNA. Differ-
entially expressed geneswere considered genes that were up-regulated
in chip-1 but down-regulated in chip-2 for each group. Hybridization
and wash processes were performed according to the manufacturer's
instructions, and the hybridized microarrays were scanned using an
AgilentMicroarray scanner G2505C. To detect signiﬁcantly differentially
expressed genes between the control and treated samples, each slide
imagewas processed usingAgilent Feature Extraction software (version
11.0.1.1). This program measures the Cy3 and Cy5 signal intensities of
whole probes. Dye bias tends to be signal-intensity-dependent; there-
fore, the software selected probes using a set-by-rank consistency ﬁlter
for dye normalization. Said normalization was performed by LOWESS
(locally weighted linear regression), which calculates the log ratio of
dye-normalized Cy3- and Cy5 signals and the ﬁnal error of the log
ratio. Statistical signiﬁcance of the log ratio values obtained for individ-
ual microarray probes was calculated using the “most conservative
error model” default function of the Feature Extraction software, by
which both a propagated and a universal error model are evaluated,
and the higher (more conservative estimate of error) p-value of two
errormodelswas reported (Agilent Technologies [55]). For the analyses,
threshold of signiﬁcant differentially expressed genes is b0.01 (for the
conﬁdence that the feature was not differentially expressed). Addition-
ally, erroneous data generated due to artifacts were eliminated before
data analysis by the software.4.6. Functional categorization of differentially expressed genes
Pathway- and disease state-focused gene classiﬁcation of the differ-
entially expressed genes in the brain were classiﬁed based on the avail-
able categories of N100 biological pathways or speciﬁc disease states in
the SABiosciences PCR array list (Qiagen; www.sabiosciences.com) for
Mus musculus.
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The biological function and network analyses were performed using
IPA (Ingenuity® Systems, www.ingenuity.com). The dataset from the
microarray [balenine diet (WME) supplementation in SAMP8 (+) or
in SAMP8 (−)], which includes the differentially expressed (≧/≦ 1.5/
0.75-fold compared with control) genes and their corresponding fold
change values, was uploaded as an Excel spread sheet into the IPA
tool. To create genenetworks, the geneswere overlaid onto a globalmo-
lecular network that was developed from information that was
contained in the ingenuity knowledge base. The functional analysis
identiﬁed the biological functions that were most signiﬁcant to the
dataset (p-value b 0.05) according to a right-tailed Fisher's exact test.
4.8. Access to gene array data
The outputs of microarray analysis used in this study are available
under the series number GSE 76459 (whole genome - http://www.
ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE76459; at the NCBI Gene
Expression Omnibus (GEO) public functional genomics data repository
(http://www.ncbi.nlm.nih.gov/geo/info/linking.html).
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.gdata.2016.09.004.
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